Obermatt

Kyowa Hakko Kirin

TYO:4151 · JP3256000005
PharmaceuticalsX-Large

360

50
Medium confidence — indicative
EV / EBIT89
Price / Owner Earnings62
Owner Earnings Yield82
Dividend Yield85
Price/Sales42
EV / Gross Profit95
Price/Book64
Return on Capital47
Cash Return on Capital23
Return on Equity27
EBIT Margin55
Gross Profitability45
Cash Conversion81
Accruals60
Owner Earnings Margin41
Sales growth37
Profit Growth69
Long-Term EPS Growth21
Owner Earnings Growth82
Reinvestment51
Price momentum60
Debt load81
Refinancing20
Debt Payback100
Liquidity79
Analyst ratings4
Opinion Changes50
Price Target Upside6
Market mood88
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kyowa Hakko Kirin clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryJapan
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeTSE
Founded1949
Employees486
ISINJP3256000005
Last UpdateApr 2, 2026
Themes
CardiovascularImmunologyHematologyOphthalmologyNephrologyDermatologyOncologyCentral Nervous SystemBiotechnologyHealth CareManufacturingScience and Engineering

Description

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas. Business Segments The company operates wi…

Analysis

Bargain bin

Kyowa Kirin Co., Ltd. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

On valuation, the picture is fair. The owner-earnings multiple stands at 19.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 6% a year, against analyst forecasts of 4%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is uncertain. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
61
2023202420252026

All-time high

83

Jan 2024

All-time low

23

Jan 2025

Average rank

60

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
42
39
36
33
Price/Earnings
52
60
56
45
Price/Book
64
62
60
59
Dividend Yield
85
75
66
59
Value (overall)
65
62
54
43

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kyowa Hakko Kirin with its peers
Medical Developments International
ASX:MVP
79
CountryAustralia
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Samsung Pharm
KSC:001360
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Korea United Pharm
KSC:033270
90
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tsumura
TYO:4540
47
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Santen Pharmaceutical
TYO:4536
65
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
HUTCHMED (China)
HKG:13
27
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →